Targeting the Tumor Stroma in Cancer Therapy

被引:29
作者
Anton, Kevin [2 ]
Glod, John [1 ,2 ]
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pediat Oncol, New Brunswick, NJ 08903 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08903 USA
关键词
MESENCHYMAL STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; METALLOPROTEINASE INHIBITOR PRINOMASTAT; PLASMINOGEN-ACTIVATOR SYSTEM; TYROSINE KINASE INHIBITOR; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; PHASE-II; MACROPHAGE INFILTRATION; PROTEIN-ALPHA;
D O I
10.2174/138920109787315088
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Increasing evidence shows that the interaction between neoplastic cells and the surrounding stroma is a critical factor in solid tumor growth. The tumor stroma is made up of diverse cellular populations including macrophages, lymphocytes, vascular cells, and carcinoma-associated fibroblasts. The complex interactions between the stroma and neoplastic cells are largely unexplored. Initial therapies aimed at disrupting angiogenesis within the tumor microenvironment have met with success in a number of tumor types. An improved understanding of stromal signaling pathways is likely to identify additional novel therapeutic targets.
引用
收藏
页码:185 / 191
页数:7
相关论文
共 99 条
[1]   High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates [J].
Alexe, Gabricla ;
Dalgin, Gul S. ;
Scanfeld, Daniel ;
Tamayo, Pablo ;
Mesirov, Jill P. ;
DeLisi, Charles ;
Harris, Lyndsay ;
Barnard, Nicola ;
Martel, Maritza ;
Levine, Arnold J. ;
Ganesan, Shridar ;
Bhanot, Gyan .
CANCER RESEARCH, 2007, 67 (22) :10669-10676
[2]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[3]   Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion [J].
Belotti, Dorina ;
Calcagno, Catia ;
Garofalo, Angela ;
Caronia, Daniela ;
Riccardi, Elena ;
Giavazzi, Raffaella ;
Tarabolettl, Giulia .
MOLECULAR CANCER RESEARCH, 2008, 6 (04) :525-534
[4]   Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].
Bergers, G ;
Song, S ;
Meyer-Morse, N ;
Bergsland, E ;
Hanahan, D .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295
[5]   Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer [J].
Bissett, D ;
O'Byrne, KJ ;
von Pawel, J ;
Gatzemeier, U ;
Price, A ;
Nicolson, M ;
Mercier, R ;
Mazabel, E ;
Penning, C ;
Zhang, MH ;
Collier, MA ;
Shepherd, FA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :842-849
[6]   PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells [J].
Boire, A ;
Covic, L ;
Agarwal, A ;
Jacques, S ;
Sherifl, S ;
Kuliopulos, A .
CELL, 2005, 120 (03) :303-313
[7]   Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery [J].
Bouzin, Caroline ;
Feron, Olivier .
DRUG RESISTANCE UPDATES, 2007, 10 (03) :109-120
[8]   A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J].
Bramhall, SR ;
Schulz, J ;
Nemunaitis, J ;
Brown, PD ;
Baillet, M ;
Buckels, JAC .
BRITISH JOURNAL OF CANCER, 2002, 87 (02) :161-167
[9]   TGFβ is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction [J].
Byrne, Scott N. ;
Knox, Matthew C. ;
Halliday, Gary M. .
IMMUNOLOGY AND CELL BIOLOGY, 2008, 86 (01) :92-97
[10]  
Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4